Products and Services
Deliverics Ltd's business is in delivering molecules into and onto cells. Cellular delivery forms the basis for many areas of research and development in the Life Sciences and is an important aspect of therapeutic treatment in many diseases. Deliverics products have been designed to efficiently deliver RNA and DNA into cells in a very gentle and non toxic manner.
Deliverics began as a spin out from the University of Edinburgh, Department of Chemistry in April 2010. The company based its first product on the work sponsored by a Scottish Enterprise Proof of Concept project led by Dr Asier Unciti-Broceta. In November 2010 the company raised initial financing to enable the launch of its first transfection product at the Medica International trade fair. We have since launched two more products and rolled out our distribution to various international markets. In the first year Deliverics Launched two products SAFEctin™ and SAFEctin STEM™ to market. With over 20 years experience in transfection our team are at the forefront in developing new solutions for cellular delivery.
Dr Steve Howell (CEO)
Dr Asier Unciti-Broceta (CSO)
Prof Mark Bradley (Chairman of the Scientific Advisory Board and non-executive Director)
Dr James Clark (non-executive Director)